For decades, Mauritius has figured among the top 10 countries with the highest incidence of type 2 diabetes (T2D). 29% of all deaths is directly linked to T2D, ranking the island as number two worldwide for diabetes-associated deaths. Among children aged 5-18 years, 22% are overweight, with elevated blood glucose levels. Due to its unique multi-ethnic population (of Indian, African, Chinese and Caucasian background) and compelling disease profile, Mauritius represents a fresh model for clinical research in T2D and related co-morbidities.

The presentation describes the local diseases and abundance of drug-naïve patients, the legal regulatory framework for conducting clinical studies, and the competence and infrastructure of the island for participating in multi-centric studies. We will also discuss the support that CIDP can offer as a CRO in facilitating clinical trials in Mauritius.

Latest News
  • 16 April 2021 CIDP Romania provides tailor-made services to substantiate your anti-acne claims!
  • 12 April 2021 CIDP has set up novel methodologies to test the antiviral efficacy of cosmetic products.
  • 19 February 2021 CIDP Romania is now Research Tax Credit accredited!
Archives

Time Zone

Choose a centre